Startups
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG
Overview
Location
United States, Connecticut, New Haven
Employees
201-500
Total raised
$114.85M
Founded date
2013
Investors 6
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| 5AM Ventures | 5amventures.com | |
| RA Capital Management | racap.com | |
| Canaan Partners | canaan.com | |
| Solasta Ventures | solasta-ventures.com | |
| New Leaf Venture Partners | nlvpartners.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Oct 21, 2015 | Series B round | $41.6M | |
| Sep 26, 2013 | Funding round | $18.25M |
Mentions in press and media 21
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 18, 2026 | Ternary Therapeutics: €4.1 Million Raised For AI-Driven Molecular Glue Drug Discovery Platform | Ternary Therapeutics, a London-based biotechnology company, has raised €4.1 million (£3.6 million) in a seed funding round to advance its artificial intelligence-powered platform for drug discovery. The round was led by daphni, with partici... |
| May 31, 2025 | Breast cancer: Pfizer-Arvinas drug beats AstraZeneca’s in delaying disease’s progression | |
| Jan 8, 2025 | Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report | Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today ... |
| Apr 9, 2018 | The biotech, digital health VC to know | Julie Papanek Grant, a partner at Silicon Valley healthcare and tech VC firm Canaan Partners, has managed to check both those boxes in the last couple of years. And while she begs off revealing what her biggest mistake has been and what she... |
| Apr 5, 2018 | Term Sheet — Thursday April 5 | GOT MONEY Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop The new company is being described as “a mentorship engine that partners with founders to solve core businesses challenges.” In r... |
| Apr 4, 2018 | Arvinas Completes $55M Series C Financing | Arvinas, LLC, a New Haven, Conn.-based biotechnology company creating a new class of drugs based on protein degradation, closed a $55m Series C financing. The round was led by new investor Nextech Invest, with participation from additional ... |
| Apr 4, 2018 | Arvinas gains $55M C round as it eyes cancer trials, pipeline work | Former Fierce 15 winner Arvinas, which has caught the attention of Pfizer and Roche over the last year, has got off a strong $55 million series C as it looks to bring its cancer candidates into the clinic. The New Haven, Conn.-based biotech... |
| Apr 4, 2018 | Arvinas Completes $55 Million Series C Financing | Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the closing of a $55 million Series C financing. The financing was led by new investor Nextech Invest, with participati... |
| Apr 4, 2018 | Arvinas Completes $55M Series C | NEW HAVEN, CT, Biotechnology company creating a new class of drugs based on protein degradation, today announced the closing of a $55 million Series C financing. >> Click here for more funding data on Arvinas >> To export Ar... |
Show more
Reviews 0
FAQ about Arvinas
When was Arvinas founded?
Arvinas was founded in 2013.
How much funding has Arvinas raised?
Arvinas has raised $114.85M in total across 3 funding rounds.
What funding rounds has Arvinas raised?
Parsers VC lists 3 funding rounds of Arvinas, among them a Series B round of $41.6M on Oct 21, 2015 and a funding round of $18.25M on Sep 26, 2013.
Who has invested in Arvinas?
Parsers VC lists 6 investors of Arvinas, among them 5AM Ventures, RA Capital Management and Canaan Partners.
What has the press written about Arvinas?
Parsers VC has collected 21 articles mentioning Arvinas, among them “Ternary Therapeutics: €4.1 Million Raised For AI-Driven Molecular Glue Drug Discovery Platform” (Mar 18, 2026) and “Breast cancer: Pfizer-Arvinas drug beats AstraZeneca’s in delaying disease’s progression” (May 31, 2025).
Is Arvinas still active?
Yes, Arvinas is active; its latest activity on Parsers VC dates from Mar 31, 2026.